Biotech Industry News 17 November 2025

Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen Inc. (NASDAQ: BIIB) is in focus on Monday, December 22, 2025—a day that combines company-specific clinical headlines with a major index event for the stock. Investors are weighing fresh long‑term data for QALSODY (tofersen) in a rare genetic form

22 December 2025

Analyst Ratings·Biotech Industry·Earnings Reports·Nasdaq Updates·Stock Market News

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is trading like a classic “deal stock” on December 22, 2025—hovering just below a fixed cash acquisition price after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to buy the company in an all-cash transaction. As of the

22 December 2025

Biotech Industry·Financial Updates·Investment Analysis·Mergers and Acquisitions·Stock Market News

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is having one of those classic biotech days where the market starts acting like it can see the future. On Monday, December 22, 2025, ZBIO surged roughly 14% and traded around $41.23 by early afternoon

22 December 2025

Biotech Industry·Clinical Trials·Financial Forecasts·Investment Analysis·Stock Market News

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (Nasdaq: FOLD) has effectively become a “deal stock” — the market is now trading the shares primarily on the odds and timing of a takeover rather than on classic biotech catalysts.

21 December 2025

Biotech Industry·Company Updates·Investment Analysis·Mergers and Acquisitions·Stock Market News

Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics, Inc. (NASDAQ: FOLD) has become one of the most closely watched rare-disease stocks heading into the final stretch of 2025 after BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus in an all-cash transaction valued at about $4.8

21 December 2025

Biotech Industry·Investment Analysis·Mergers and Acquisitions·Stock Market News

Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is having the kind of week biotech traders both crave and fear: a sudden, definitive catalyst that snaps the stock to a new reality overnight. On Friday, December 19, shares jumped about 30% and hovered

20 December 2025

Biotech Industry·Investment Analysis·Mergers & Acquisitions·Stock Market News

Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

December 18, 2025 — Merck & Company, Inc. (NYSE: MRK) is back in the spotlight for investors today as three threads converge: a fresh Wall Street upgrade tied to Merck’s post‑Keytruda strategy, a potentially meaningful FDA fast‑track development for two

18 December 2025

Biotech Industry·FDA Approvals·Investment News·Pharmaceuticals·Stock Market

Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics Inc. (NASDAQ: SMMT) continues to trade like a classic high-beta biotech: big promises in lung cancer, plenty of red flags, and a stock price stuck near the lower end of its 52-week range while analysts project eye-popping upside.

9 December 2025

Biotech Industry·Financial News·Investment Analysis·Risk Management·Stock Market

Moderna (MRNA) Stock on 8 December 2025: Institutional Tug‑of‑War, FDA Shockwaves and 2026–2030 Forecasts

Published: 8 December 2025 – all data and news current to this date. This article is informational only and not investment advice. Key takeaways Where Moderna stock stands today As of 8 December 2025, Moderna shares trade around $27.70, roughly

8 December 2025

Biotech Industry·FDA News·Investment Strategies·Market Forecasts·Stock Analysis

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters The move deepens J&J’s bet on

17 November 2025

Biotech Industry·Mergers & Acquisitions·Pharmaceuticals

Biotech Industry News 17 November 2025 - 22 December 2025